Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually

Stock Information for Cosmos Health Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cosmos Health Inc.

Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy
Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement
Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million
Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility
Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units
Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation
Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.